|
World
Tuberculosis Day: 24 March 2012
‘ Let us Unite to Stop TB’
 Game: Check your TB knowledge
|
|
Tuberculosis
that is “resistant to all drugs”
 Recently, a published
study described four patients from India with resistance to all
tested drugs for tuberculosis (TB).
WHO defines the cases of drug-resistant TB in India as extensively-drug
resistant TB or XDR-TB, as reliable tests to confirm total resistance to
some TB drugs are not available. These serious cases raise the alarm for
better managed TB care and treatment, particularly in the private sector.
Severe resistance to available medicines occurs when below-standard care
and treatment by health providers is allowed to go unchecked. WHO is working closely with the Indian
Ministry of Health and Family Welfare to provide accurate diagnostic and
treatment advice to those affected and to strengthen the surveillance system.
More Info…
|
|
Fifteenth
Meeting of National TB Programme Managers and Partners, 6-9 December 2011
 The 15th Meeting of the National TB
Programme Managers and Partners of the WHO South-East Asia Region was held
in Bangkok, Thailand on 6- 9 December 2011.
The general objectives of the meeting were to further strengthen and
improve implementation of the Stop TB Strategy towards achieving TB targets
as per the Millennium Development Goals (MDGs), in all Member countries.
Participants from the national TB programmes in
Member countries of the Region, representatives from technical agencies,
and WHO TB staff from the HQ, SEARO and Country offices, attended this
4-day meeting.
More Info…
|
|
 International
Trainings and Workshops on TB
National TB Programme
Managers of the Region adopt new target for TB control
National AIDS and TB
Managers of the SEA Region focus on accelerating interventions to address
HIV associated TB.
|
|
The TB Unit of the WHO Regional Office for South-East
Asia assists countries in the Region in achieving set targets for TB control through policy guidance, advocacy, planning, information exchange, technical support, assistance for human resource development, resource mobilization, monitoring and evaluation and operational
research. Under the Regional Strategic Plan 2006–2015, intensified
action to add impetus to current efforts and promote additional
interventions for TB control is envisaged.
|
|
Highlights
|
|
Continued progress in TB
Control in the SEA Region  Countries in the WHO
South East Asia (SEA) Region have made significant progress towards the TB
related MDGs. The estimated incidence of all forms of TB, estimated prevalence
of all forms of TB and the estimated TB mortality all continue to show a
downward trend. The treatment success rate among new smear positive
pulmonary TB cases has remained above 85% since 2005, and is 88% for the
cases registered in 2009.
More…
|
|
NEWS UPDATES
|
|
Steady progress made towards treating TB in Timor-Leste
|
|
Dili: A greater number of new positive
Tuberculosis (TB) cases are being detected now in Timor-Leste compared to nine
years ago. Of these new cases, about 85% are being successfully treated.
Timor Leste’s TB burden was first recorded in
1995 and averaged 707 cases per 100,000 of its population. Today it stands
at 378 cases per 100,000 of its population. “Timor-Leste is on track to
meeting the MDG goal of halving the number of TB cases in the country by
2015. The firm and dedicated support from both our national and
international partners have been significant in the control of TB in
Timor-Leste” said Dr Martins at the launch of the country's Stop TB Strategy
for 2011-2015. More…
[PDF 136 KB]
|
|
Stop TB Partnership warns of a temporary shortage of
quality-assured Streptomycin
|
|
Geneva - 10 November 2010 - The Stop TB
Partnership anticipates a temporary shortage of quality-assured
Streptomycin. This shortage, which is also affecting other suppliers, is
related to quality issues of the Active Pharmaceutical Ingredient (API)
source used by one of the main Streptomycin suppliers of the Partnership's
Global Drug Facility (GDF). Additionally, as major donors and technical
agencies have adopted more stringent quality assurance policies, GDF is not
in the short-term able to secure sufficient quantities of Streptomycin that
meet the new stringent criteria. More…
|
|
TB Alliance
Launches First Clinical Trial of a Novel TB Drug Regimen
|
|
BERLIN, Germany —
8 November 2010 - In advance of the 41st Union World Conference, the
Global Alliance for TB Drug Development (TB Alliance) today announced the
launch of the first clinical trial to test a novel tuberculosis regimen in
a new development paradigm designed to speed new treatments to patients.
This novel three-drug combination shows promise to treat both
drug-sensitive (DS-TB) and multidrug-resistant TB (MDR-TB), and alter the
course of the TB pandemic by shortening and simplifying treatment
worldwide. More…
|
| News home
>
|
